GAC - You call it the grand slam I call it triplets it's all the same thing. 

If we we have triplets the company won't be able to answer the volume of calls they will be getting quick enough. How many drugs have had a 30% or greater RRR? How many drugs safely increase eGFR...none? How many drugs have seen patients MoCA scores increase...none? There is zero competition for CKD and cognition drugs that do what apabetalone may do. If we have triplets it's not big news, it's huge news. If anything the company may have to tamp down expectations. In that situation the people that own the shares today will have the big challenge of when to sell and how many they want to sell before the inevitable bubble will eventually burst. That is a pretty bold statement but look at Bio Gene last July when they first brought out there Alzheimer's trial results and then full data. Tilray had a similar run up and down not long after they got their NASDAQ listing as well. IMO the talking heads won't be able to get enough information about the drug, epigenetics and the company quick enough. 

We must first pass BoM with statistical significance though before any of those dreams have a chance of coming true.

All IMO, dyodd.

tada